Analytical Data
-
Gene name
CYP2C19
- Application
-
Alternative Names
(R)-limonene 6-monooxygenase ((S)-limonene 6-monooxygenase) ((S)-limonene 7-monooxygenase) (CYPIIC17) (CYPIIC19) (Cytochrome P450-11A) (Cytochrome P450-254C) (Fenbendazole monooxygenase) (Mephenytoin 4-hydroxylase)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P33261
-
Expression Region
26-490aa
-
Molecular Weight
60.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2C19 is a member of the cytochrome P450 superfamily of enzymes, which play a crucial role in the metabolism of various drugs and endogenous compounds. Variability in CYP2C19 activity due to genetic polymorphisms significantly influences individual responses to medications, particularly in the context of antiplatelet agents like clopidogrel and proton pump inhibitors. Individuals can be categorized as poor, intermediate, extensive, or ultra-rapid metabolizers based on their CYP2C19 genotype, impacting therapeutic efficacy and risk for adverse drug reactions. Given its critical role in pharmacogenetics, there has been a growing interest in studying recombinant CYP2C19 proteins to elucidate their structure-function relationships, investigate metabolic pathways, and assess drug interaction mechanisms. The production of recombinant CYP2C19 proteins allows for advanced in vitro studies, facilitating the exploration of substrate specificity, enzyme kinetics, and the impact of genetic variants on enzyme activity. This research is pivotal for personalized medicine, enabling tailored pharmacotherapy and optimizing drug dosing strategies based on an individual’s genetic makeup. Understanding the biochemical properties and functional implications of CYP2C19 through recombinant technology will enhance our capability to predict drug metabolism profiles and improve treatment outcomes in diverse patient populations.
